Candriam SCA’s Aegerion Pharmaceuticals AEGR Stock Holding History

Candriam SCA’s Portfolio AEGR Stock Details AEGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-126,000	Closed	-$464K	–	693
2016 Q1	$464K	Buy	+126,000	New	+$780K	0.01%	562
2015 Q4	–	Sell	-115,800	Closed	-$1.57M	–	655
2015 Q3	$1.57M	Buy	115,800 +1,800	+2%	+$32K	0.04%	374
2015 Q2	$2.16M	Hold	114,000	–	–	0.05%	351
2015 Q1	$2.98M	Buy	114,000 +34,000	+43%	+$865K	0.06%	338
2014 Q4	$1.68M	Buy	+80,000	New	+$2.02M	0.04%	380

Other funds holding AEGR

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Candriam SCA's AEGR Position: Q2 2016 in Review

Candriam SCA sold out of Aegerion Pharmaceuticals (AEGR) in Q2 2016, closing a stake of 126,000 shares — an estimated $464K sold.

Candriam SCA first reported a position in AEGR in Q4 2014 and held it in 5 quarters. The position peaked at $2.98M in Q1 2015. 71 funds tracked by Wall St. Rank hold AEGR as of Q2 2016.

Candriam SCA reported no remaining Aegerion Pharmaceuticals position as of Q2 2016 after selling out during the quarter.
Candriam SCA sold 126,000 Aegerion Pharmaceuticals shares in Q2 2016, an estimated $464K.
Candriam SCA first reported a position in Aegerion Pharmaceuticals in Q4 2014 and held it in 5 quarters.
Candriam SCA's Aegerion Pharmaceuticals position peaked at $2.98M in Q1 2015.
71 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q2 2016.

Based on Candriam SCA's 13F filing for Q2 2016, filed 26 Jul 2016.